Journal of Antimicrobial Chemotherapy (1983) 12, 503-506
© 1983 The British Society for Antimicrobial Chemotherapy
research-article |
In- vivo effect of novobiocin on primary cytomegalovirus infection
Institute of Microbiology, School of Medicine, University of Bologna Bologna, Italy
accepted 27 June 1983
Dr Maria Paola Landini, Institute of Microbiology, University of Bologna, School of Medicine, c/o St. Orsola General Hospital, Via Massarenti 9, 40138 Bologna, Italy.
0.5 mM of novobiocin completely suppresses the replication of human cytomegalovirus (HCMV) in vitro. Based on the evidence that murine cytomegalovirus (MCMV) titres were reduced in vitro by 60% with the same concentration of the drug, the in vivo antiviral activity of novobiocin has been tested in the murine model. The results showed that if treatment started before the infection virus was not isolated from parenchymal organs during treatment. Virus could be isolated 24 h after stopping treatment, but not from kidney or spleen.